A pill that digests gluten before your immune system can react to it — that is the promise of enzyme therapy for celiac disease. Scientists have known for years that certain enzymes can break down the gluten proteins that trigger intestinal damage in celiac patients. So why, after more than two decades of research, is there still no approved enzyme drug? A new review published in Current Medicinal Chemistry traces the history of that failure — and explains why the approach still has genuine promise.
For celiac families who have watched one treatment candidate after another stall out before reaching patients, that combination of honest failure analysis and forward-looking roadmap is worth understanding.
What This Means for You
If you have followed celiac treatment news, you have probably seen headlines about enzyme therapies. The concept is intuitive: take a pill with your meal that breaks down gluten in your stomach, and the punishing strictness of the gluten-free diet becomes less of a medical emergency. Cross-contact at a restaurant, trace amounts from a shared kitchen — these would matter far less than they do today.
The frustrating reality is that no such pill exists. This new review, authored by researchers Andrey Zamyatnin and Lyudmila Savvateeva, explains why the gap between laboratory success and an approved drug has remained so wide. They identify four specific problems that have tripped up drug developers repeatedly. None are insurmountable — but solving them requires the field to be more systematic than it has been.
For celiac patients and their families, the message is not encouraging in the short term. No enzyme drug is imminent. But this kind of sober failure analysis is real progress. Understanding exactly where things went wrong is what allows the next generation of research to go differently. As the dad of a son with celiac disease, I find this type of stocktaking more reassuring than breathless announcements of breakthroughs that quietly disappear from the headlines two years later.
We have previously covered upcoming enzyme-based and luminal treatments and targeted enzymatic approaches for coeliac disease in depth. What this new review adds is a systematic diagnosis of why the field has stalled — and what an enzyme candidate would actually need to clear the bar for regulatory approval.
Key Takeaways
- Scientists have been developing enzyme therapies for celiac disease for over 20 years. Not one has received regulatory approval.
- Four obstacles have blocked progress: the variability of gluten proteins, stomach acid destroying the enzymes, unpredictable enzyme activation, and no shared standard for testing effectiveness.
- An ideal therapeutic enzyme would need to work against many types of gluten, survive stomach acid, and activate consistently in the gut.
- The authors conclude the enzyme approach is scientifically sound — the field needs better-designed candidates and more rigorous testing methods to move forward.
- The strict gluten-free diet remains the only proven treatment for celiac disease today.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
Why Enzymes Were a Logical Target
Celiac disease is triggered by gluten — a family of proteins found in wheat, barley, and rye. When someone with celiac consumes gluten, fragments of those proteins survive normal digestion and reach the lining of the small intestine. There, the immune system recognizes certain fragments as threats and attacks — causing intestinal damage that leads over time to nutrient malabsorption and a cascade of health problems.
The critical word in that sequence is “survive.” The human digestive system breaks down most food proteins efficiently, but gluten is unusually resistant. It contains long stretches of two amino acids — proline and glutamine — that our own digestive enzymes struggle to cut through. This resistance is what makes gluten immunogenic (capable of triggering an immune response) in ways that most food proteins are not.
The logical response: introduce an enzyme specifically designed to cut those proline-rich sequences. Break the dangerous gluten fragments in the stomach or upper gut before they ever reach the small intestine, and you remove the trigger. This is the basic logic behind glutenases — enzymes derived from microorganisms or fungi that can degrade the parts of gluten that human digestion cannot.
Four Reasons the Drug Never Arrived
1. Substrate heterogeneity. Gluten is not a single protein. It is a large family of related proteins — wheat alone contains hundreds of distinct gluten epitopes (the specific molecular sequences that the immune system targets). An enzyme that degrades one type of gluten protein may miss others entirely. Drug developers have repeatedly underestimated how broad that coverage needs to be to actually protect patients.
2. The gastric environment. The stomach is highly acidic, with a pH as low as 1 to 2. Those conditions destroy most proteins, including the enzymes being developed as treatments. A drug taken orally needs to survive that environment long enough to reach the small intestine or upper digestive tract where it can do its work. Many enzyme candidates that performed well in laboratory conditions simply fell apart in the stomach before becoming effective.
3. Unreliable zymogen activation. Many enzyme candidates are synthesized as zymogens — inactive precursor forms that require a specific biochemical trigger to switch on. In theory, this is elegant: a zymogen could be engineered to activate only in the right part of the digestive tract, turning on precisely where it is needed. In practice, that activation has been inconsistent — too early, too late, or not at all. A drug that activates unpredictably cannot be prescribed reliably.
4. No standardized testing. Perhaps the most avoidable failure is also one of the most persistent. There is no agreed-upon method for simulating human digestion in the laboratory to evaluate how well an enzyme candidate actually works. Different research groups use different models, making it nearly impossible to compare results across studies. A promising result in one lab may not hold up elsewhere simply because the testing conditions differ. This has wasted time and obscured which candidates genuinely deserved more investment.
What a Viable Enzyme Would Need
The review does not only diagnose — it maps what success would look like. An enzyme drug with a realistic path to approval would need to satisfy three criteria simultaneously:
- Degrade a wide range of gluten epitopes, not just the most common ones, to protect against the full diversity of gluten proteins across wheat, barley, and rye
- Remain stable and catalytically active under the acidic conditions of the stomach
- Activate predictably in vivo (inside the body), producing consistent effects from one dose to the next
The authors point to certain prolyl endopeptidases — enzymes that cut proteins specifically at proline residues, sourced from bacteria and fungi — as strong candidates if they can be engineered to meet all three criteria. The call for standardized testing protocols is equally important: without a shared benchmark, the field cannot learn efficiently from its own results.
The conclusion Zamyatnin and Savvateeva reach is that the enzymatic strategy is fundamentally sound. The barriers are real but specific. Progress now depends on researchers building candidates to a clearer set of requirements and evaluating them against consistent standards. That is a more tractable problem than “enzymes don’t work” — which is what years of stalled trials might suggest.
For a broader view of where celiac treatment research is heading beyond enzymes, see our earlier coverage of novel therapeutic frontiers in celiac disease.
Related Coverage
- Targeted enzymatic therapy for coeliac disease
- Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
- Beyond gluten-free diet: Novel therapeutic frontiers in celiac disease armamentarium
References
- Zamyatnin AA, Savvateeva LV. “Celiac Disease Enzyme Therapy: Why Is There Still No Approved Drug?” Current Medicinal Chemistry. 2026 Jul 16. doi: 10.2174/0109298673492102260702074316